Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS)(OTCQX:SCTPF), an
immuno-oncology company developing cancer stem cell-related therapeutics, today
announces that its common shares have been approved for listing and will
commence trading on the Toronto Stock Exchange ("TSX") at the opening of the TSX
on April 22, 2014. The Company's common shares will continue to trade under the
trading symbol "SSS" and its common shares will be delisted from the TSX Venture
Exchange concurrent to the commencement of trading on the TSX. 


"Graduation to the TSX is one of several important corporate milestones we aim
to achieve this year as we continue to grow our company," commented Dr. Niclas
Stiernholm, CEO of SCT. "Listing on the TSX is expected to provide the company
with improved access to the capital markets and greater recognition among
healthcare investors." 


The company also announced that the Board of Directors has granted options to
purchase 7,923,868 common shares of the company to its executive officers. The
options were issued at an exercise price of $0.345 per share for a ten-year
term. The grant of options is subject to acceptance by the TSX Venture Exchange.
SCT has approximately 344 million shares outstanding on a fully diluted basis.


About Stem Cell Therapeutics: 

Stem Cell Therapeutics Corp. (SCT) is an immuno-oncology company advancing
cancer stem cell discoveries into novel and innovative cancer therapies. The
Company has two premier preclinical programs, SIRPaFc and a CD200 monoclonal
antibody (mAb), which target two key immunoregulatory pathways that tumor cells
exploit to evade the host immune system. SIRPaFc is an antibody-like fusion
protein that blocks the activity of CD47, a molecule that is upregulated on
cancer stem cells in AML and several other tumors. The CD200 mAb is a fully
human monoclonal antibody that blocks the activity of CD200, an
immunosuppressive molecule that is overexpressed by many hematopoietic and solid
tumors. SCT's clinical stage programs include the recently in-licensed program
focused on the structure of tigecycline, which is currently being evaluated in a
multi-centre Phase I study in patients with acute myeloid leukemia (AML), as
well as TTI-1612, a non-cancer stem cell asset that recently completed a
28-patient Phase I trial in interstitial cystitis ("IC") patients. For more
information, visit: www.stemcellthera.com 


Caution Regarding Forward-Looking Information: 

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include changing market conditions; the successful and timely completion
of pre-clinical and clinical studies; the establishment of corporate alliances;
the impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
James Parsons
Chief Financial Officer
+1 416 595 0627
jparsons@stemcellthera.com
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Sunvest Minerals Corp Charts.
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Sunvest Minerals Corp Charts.